C11orf10_1810006K21Rik Inhibitors
Chemical inhibitors of C11orf10 target various signaling pathways that regulate the protein's activity within the cell. Wortmannin and LY294002 are both inhibitors of phosphoinositide 3-kinases (PI3K), which play a pivotal role in the PI3K-AKT signaling pathway. Inhibition by these chemicals can reduce the phosphorylation and activation of AKT, a kinase that is often upstream of various proteins, including C11orf10. By attenuating AKT activity, the phosphorylation-dependent functions of C11orf10 can be disrupted. Similarly, Dasatinib and PP2, which selectively inhibit Src family kinases, can lead to reduced activation of C11orf10. Src family kinases are part of intricate signaling networks, and their inhibition by these chemicals can impede the engagement of C11orf10 in cellular processes.
Further down the line of kinase inhibitors, U0126 and PD98059 specifically inhibit MEK1/2, key kinases in the MAPK/ERK pathway. The MAPK/ERK pathway is a critical regulator of many cellular functions, and by preventing the activation of MEK, these inhibitors can indirectly lead to decreased activity of C11orf10 if it is regulated through this pathway. SB203580 and SP600125 target the p38 MAPK and JNK, respectively, both of which are members of the MAPK family. Inhibition of these kinases can suppress the associated signaling pathways that might be required for the full functionality of C11orf10. On a different spectrum, GF109203X and Go6983 disrupt protein kinase C (PKC) signaling. Since PKC is involved in numerous cellular functions, blocking this pathway can decrease C11orf10 activity if it relies on PKC-mediated signaling. Lastly, inhibitors like Rapamycin and AZD8055, which target mTOR and its associated complexes, can lead to reduced signaling through pathways that involve C11orf10. The inhibition of mTORC1 and mTORC2 by these chemicals can, therefore, impede the functional activity of C11orf10, assuming it operates downstream or is regulated by mTOR-dependent signaling.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases (PI3K), which can lead to reduced phosphorylation and activation of AKT. As PI3K-AKT signaling is involved in numerous cellular processes, this inhibition can diminish C11orf10 activity by reducing its downstream signaling efficiency. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents AKT phosphorylation and activation. By curtailing the PI3K-AKT pathway, LY294002 can reduce signaling cascades that are essential for C11orf10 activity, resulting in functional inhibition of C11orf10. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib selectively inhibits Src family kinases, which are part of signaling pathways that interact with C11orf10. The inhibition of these kinases can lead to decreased activation of molecular pathways that contribute to the functional activity of C11orf10. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2, like Dasatinib, inhibits Src family kinases, leading to reduced signaling through pathways that involve C11orf10. This inhibition can consequently decrease the functional activity of C11orf10 by preventing its interaction or modulation by Src-related pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK/ERK pathway. By obstructing MEK activity, U0126 impairs the activation of ERK, which may be necessary for the full functional activation of C11orf10, thereby inhibiting its activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1/2, which impedes the MAPK/ERK pathway. The inhibition of this pathway can lead to reduced functional activity of C11orf10 if its activity is mediated through ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. By inhibiting p38 MAPK, this chemical can suppress pathways that contribute to the activation and functionality of C11orf10, leading to its functional inhibition. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, another member of the MAPK family. JNK pathways can be involved in the regulation of C11orf10 activity; thus, inhibition of JNK can result in decreased activation and subsequent functional inhibition of C11orf10. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
GF109203X is a potent inhibitor of protein kinase C (PKC). Inhibition of PKC can lead to a decrease in C11orf10 activity if C11orf10 requires PKC-mediated signaling for its functionality. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 inhibits PKC isoforms. By disrupting PKC signaling pathways, Go6983 can inhibit the functional activity of C11orf10 that relies on PKC signaling for its action within the cell. | ||||||